NCT00003652 is a Phase 3 clinical trial of cisplatin in Anal Cancer, sponsored by UNICANCER.

Who is sponsoring NCT00003652?

NCT00003652 is sponsored by UNICANCER.

What drugs are being tested in NCT00003652?

Interventions in NCT00003652: cisplatin, fluorouracil, neoadjuvant therapy, radiation therapy.

What condition does NCT00003652 study?

NCT00003652 studies Anal Cancer.

Is NCT00003652 still recruiting?

NCT00003652 is currently completed. Last updated 17 February 2021.

Last reviewed 2021-02-17 · How we verify

NCT00003652

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Completed Phase 3 Last updated 17 February 2021

What this trial tests

Phase 3 trial testing cisplatin in Anal Cancer in 350 participants. Completed in 31 March 2007.

Timeline

4 January 1999

Primary endpoint
1 April 2006

31 March 2007

Quick facts

Lead sponsor	UNICANCER
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Primary purpose	treatment
Enrollment	350
Start date	4 January 1999
Primary completion	1 April 2006
Estimated completion	31 March 2007
Sites	48 locations across France

Drugs / interventions tested

cisplatin (cisplatin) — full drug profile →
fluorouracil — full drug profile →
neoadjuvant therapy — full drug profile →
radiation therapy

Conditions studied

Anal Cancer — all drugs for Anal Cancer →

Sponsor

UNICANCER — full company profile →

Who can join

Adults 0 to 80, any sex, with Anal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: This randomized phase III trial is studying different regimens of giving combination chemotherapy together with radiation therapy and comparing how well they work in treating patients with stage II or stage III anal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of cisplatin

Trials testing the same drug.

NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun · Phase 1, PHASE2 · not yet recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT06924619 — Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma · Phase 2 · recruiting
NCT06151574 — Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer W · Phase 3 · active not recruiting
NCT06081673 — Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC · Phase 2 · recruiting

Other recruiting trials for Anal Cancer

Currently open trials in the same condition.

NCT07192055 — Self-sampling to Optimize Anal Lesion Outcomes · NA · recruiting
NCT07296237 — Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer · recruiting
NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
NCT06670495 — HPV Genotype Attribution and Disease Burden of Anal Cancer in China · recruiting

Other UNICANCER trials

Trials by the same sponsor.

NCT07340619 — Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
NCT07360834 — Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndr · NA · not yet recruiting
NCT07106632 — Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests · Phase 3 · not yet recruiting
NCT07294430 — Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate. · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00003652 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNICANCER
Last refreshed: 17 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00003652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing